Skip to main content
SpringerLink
Log in

Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background

Olaparib is a first-in-class potent oral poly(ADP-ribose) polymerase inhibitor.

Objectives

The aims of this analysis were to establish an integrated population pharmacokinetic (PK) model of olaparib in patients with solid tumors and to bridge the PK of olaparib between capsule and tablet formulations.

Methods

The population PK model was developed using plasma concentration data from 659 patients in 11 phase I, II, and III studies of olaparib tablets/capsules monotherapy. Relative bioavailability between the tablet and capsule formulations was estimated and the relative exposure between olaparib tablet and capsule therapeutic doses was further assessed.

Results

The concentration–time profile was described using a two-compartment model with sequential zero- and first-order absorption and first-order elimination for both capsules and tablets with different absorption parameters. Multiple-dose clearance compared with single-dose clearance was reduced by approximately 15% (auto-inhibition). Disease severity had an impact on olaparib clearance, and tablet strength had an impact on Ka. The olaparib geometric mean area under the curve (AUC) and maximal concentration (Cmax) following a single 300 mg tablet were 42.1 μg h/mL and 5.8 μg/mL, respectively, and the steady-state geometric mean AUC and Cmax following a 300 mg tablet twice daily were 49.0 μg h/mL and 7.7 μg/mL, respectively. The relative exposure (AUC) of the 300 mg tablet formulation is 13% higher than the 400 mg capsule formulation.

Conclusion

This analysis bridged the olaparib capsule and tablet formulation PK and provided key assessment to support the approval of the olaparib tablet formulation in patients with ovarian cancer, regardless of their BRCA mutation status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547–60.

    Article  CAS  PubMed  Google Scholar 

  2. FDA. Lynparza prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf. Accessed 11 June 2018.

  3. European Medicines Agency. Lynparza (olaparib); EPAR. 2015. http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/003726/human_med_001831.jsp. Accessed 11 June 2018.

  4. Mateo J, et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Target Oncol. 2016;11:401–15.

    Article  CAS  PubMed  Google Scholar 

  5. Mateo J, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ang JE, et al. A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments. Eur J Cancer Suppl. 2010;8:128–9.

    Article  Google Scholar 

  7. Dirix L, et al. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies. Clin Ther. 2016;38:2286–99.

    Article  CAS  PubMed  Google Scholar 

  8. McCormick A, Swaisland H, Reddy VP, Learoyd M, Scarfe G. In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450. Xenobiotica. 2018;48(6):555–64.

    Article  CAS  PubMed  Google Scholar 

  9. Plummer R, et al. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2015;76:723–9.

    Article  CAS  PubMed  Google Scholar 

  10. Rolfo C, et al. Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv Ther. 2015;32:510–22.

    Article  CAS  PubMed  Google Scholar 

  11. Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–57.

    Article  PubMed  Google Scholar 

  12. Xu H, Li J, Learoyd M, Bui K, Tomkinson H, Al-Huniti N. Population pharmacokinetic (PK) and exposure haemoglobin response analysis for olaparib tablet formulation. Clin Pharmacol Ther. 2017;101(Suppl 1):S92.

    Google Scholar 

  13. Li J, Xu H, Learoyd M, Bui K, Tomkinson H, Al-Huniti N. Population pharmacokinetic (PopPK) and exposure response (E-R) analyses for olaparib tablet formulation in a Phase III study (SOLO2) in patients with ovarian cancer. J Pharmacokinet Pharmacodyn. 2017;44(Suppl 1):133.

    Google Scholar 

  14. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–51.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Xu H, et al. Evaluation of aztreonam dosing regimens in patients with normal and impaired renal function: a population pharmacokinetic modeling and Monte Carlo simulation analysis. J Clin Pharmacol. 2017;57:336–44.

    Article  CAS  PubMed  Google Scholar 

  16. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558–69.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Peer CJ, et al. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women’s cancers. Cancer Chemother Pharmacol. 2017;80:165–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Pujade-Lauraine E, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84.

    Article  CAS  PubMed  Google Scholar 

  19. Ledermann J, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.

    Article  CAS  PubMed  Google Scholar 

  20. Houk BE, et al. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15:2497–506.

    Article  CAS  PubMed  Google Scholar 

  21. Yamamoto N, et al. A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci. 2012;103:504–9.

    Article  CAS  PubMed  Google Scholar 

  22. Fong PC, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34.

    Article  CAS  PubMed  Google Scholar 

  23. Tutt A, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–44.

    Article  CAS  PubMed  Google Scholar 

  24. Audeh MW, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245–51.

    Article  CAS  PubMed  Google Scholar 

  25. Kaye SB, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30:372–9.

    Article  CAS  PubMed  Google Scholar 

  26. Yonemori K, et al. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol. 2016;78:525–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the patients, their families, and all investigators and study personnel involved. They would also like to acknowledge the programmers who supported the compilation of the dataset, Mihai Surducan of Mudskipper Ltd for medical writing assistance funded by AstraZeneca, and the FDA pharmacometric reviewers Chao Liu, Jingyu Yu, and Yaning Wang for their comments. This study was sponsored by AstraZeneca.

Author information

Authors and Affiliations

  1. Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Boston, MA, 02451, USA

    Diansong Zhou, Jianguo Li, Khanh Bui, Nidal Al-Huniti & Hongmei Xu

  2. Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, UK

    Maria Learoyd, Alienor Berges & Helen Tomkinson

  3. Global Medicine Development, AstraZeneca, Cambridge, UK

    Tsveta Milenkova

Authors
  1. Diansong Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianguo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Khanh Bui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Learoyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alienor Berges
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsveta Milenkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nidal Al-Huniti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Helen Tomkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hongmei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hongmei Xu.

Ethics declarations

Funding

This study was funded by AstraZeneca.

Conflict of interest

Diansong Zhou, Maria Learoyd, Alienor Berges, Tsveta Milenkova, Nidal Al-Huniti, Helen Tomkinson, and Hongmei Xu are employees of and shareholders in AstraZeneca. Jianguo Li and Khanh Bui are former employees of AstraZeneca.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in this study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 20 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, D., Li, J., Bui, K. et al. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clin Pharmacokinet 58, 615–625 (2019). https://doi.org/10.1007/s40262-018-0714-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-018-0714-x

Search

Navigation